Vaxcyte Inc
5VA
Company Profile
Business description
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Contact
825 Industrial Road
Suite 300
San CarlosCA94070
USAT: +1 650 837-0111
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
507
Stocks News & Analysis
stocks
ASX miner weathers the storm with strong commodity prices
Lower volumes due cyclone activity but revenues hold steady.
stocks
Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure
We’ve raised our fair value estimate of Lilly stock.
stocks
OpenAI missed multiple revenue targets - here’s why it likely won’t IPO this year
Plus, whichever AI company IPOs first defines what “good” looks like.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.70 | 21.20 | -0.24% |
| CAC 40 | 8,114.84 | 0.00 | 0.00% |
| DAX 40 | 24,292.38 | 337.82 | 1.41% |
| Dow JONES (US) | 49,499.27 | 152.87 | -0.31% |
| FTSE 100 | 10,363.93 | 14.89 | -0.14% |
| HKSE | 25,776.53 | 335.31 | -1.28% |
| NASDAQ | 25,114.44 | 222.13 | 0.89% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,039.20 | 135.89 | 1.05% |
| S&P 500 | 7,230.12 | 21.11 | 0.29% |
| S&P/ASX 200 | 8,729.80 | 21.20 | -0.24% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |